[Featured Stock] Chong Kun Dang Rises on News of Entering Phase 3 Clinical Trial for Nafamostat... "Increased Potential as COVID-19 Treatment"

[Asia Economy Reporter Hyunseok Yoo] Chong Kun Dang and Newgelab are showing strong performance. It appears that the news of the Korea Pasteur Institute entering Phase 3 clinical trials of Nafamostat as a treatment for COVID-19 in Senegal has had an impact.

As of 3:02 PM on the 31st, Chong Kun Dang was trading at 194,500 KRW, up 6.28% (11,500 KRW) from the previous trading day. Newgelab is also up 1.71%.

According to a media outlet and the clinical trial information site under the U.S. National Institutes of Health on the same day, the Korea Pasteur Institute plans to evaluate the efficacy and safety of the treatment regimen in adult COVID-19 patients (Phase 3 clinical trial) in collaboration with one of the Senegalese research institutes, Pasteur de Dakar, the Senegal Ministry of Health, and Senegal Fann Hospital. As of mid-month, 186 patients have been recruited, and Nafamostat will be administered for 10 to 14 days depending on the severity and underlying conditions of the clinical trial participants.

Earlier, on the 4th, the infectious disease professor team led by Lee Ji-young and Jang Seok-bin at Dankook University Hospital announced results from clinical trials of Nafamostat, a candidate drug for COVID-19 treatment, reporting that all three confirmed patients were fully cured.

Nafamostat is a pharmaceutical ingredient used to prevent blood clotting in patients undergoing hemodialysis and to treat acute pancreatitis. It is known to show excellent effects in improving acute pneumonia symptoms caused by COVID-19 infection. It is also reported to have more than 600 times the antiviral efficacy in human lung cell experiments compared to Remdesivir.

This content was produced with the assistance of AI translation services.